BENITIONSClinical Trial Intelligence

Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease

第2相 完了 NCT06350123

対象疾患Chronic Kidney Disease
第2相
スポンサーAstraZeneca
ステータス完了
参加者数324 名
介入(薬剤)Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin
開始日2024年5月1日
完了日2025年5月9日
結果公開日2026年6月26日

概要

The purpose of the study is to evaluate the efficacy, safety and tolerability of balcinrenone/dapagliflozin compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria. This study will evaluate the effect of the balcinrenone/dapagliflozin on urinary albumin-to-creatinine ratio (UACR), compared with dapagliflozin in patients with CKD. This is a dose-finding study aiming to identify an optimal dose of balcinrenone/dapagliflozin for a future Phase III study in patients with CKD.

Relative Change in Urine Albumin-to-Creatinine Ratio (UACR) From Baseline to Week 12

Baseline (Day 1) until Week 12 (Day 85) · mg/g

Balcinrenone/Dapagliflozin 15 mg/10 mg0.76 mg/g
Balcinrenone/Dapagliflozin 40 mg/10 mg0.66 mg/g
Dapagliflozin 10 mg0.98 mg/g
p-value<0.001
Percent change difference-32.77 (95% CI -41.96–-22.14)

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

すべての治験

このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。